THERAPEUTICS
Rosuvastatin prevented major cardiovascular events in people with elevated C-reactive protein
| The first 150 words of the full text of this article appear below. |
P M Ridker
Dr P M Ridker, Brigham and Womens Hospital, Boston, MA, USA; pridker@partners.org
STUDY DESIGN
randomised placebo-controlled trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin [JUPITER]). ClinicalTrials.gov NCT00239681 [ClinicalTrials.gov] .
concealed.*
blinded (patients, clinicians, data collectors, and outcome adjudication committee).*
STUDY QUESTION
1315 sites in 26 countries.
17 802 men
50 years of age or women
60 years of age (mean age 66 y, 62% men) who had no history of cardiovascular (CV) disease, high-sensitivity C-reactive protein concentrations
2.0 mg/l, low-density lipoprotein cholesterol levels <3.4 mmol/l (130 mg/dl), and triglyceride concentrations <5.6 mmol/l (500 mg/dl). Exclusion criteria included previous use of a lipid-lowering drug; uncontrolled hypertension or hypothyroidism; and diabetes.
rosuvastatin, 20 mg daily (n = 8901), or placebo (n = 8901) for
5 years.
composite of CV events (non-fatal myocardial infarction or stroke, hospital admission for unstable angina, arterial revascularisation procedure, or confirmed CV death), components
University of Michigan, Flint, Michigan, USA
Mayo Clinic, Rochester, Minnesota, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
